Egalet's Guardian Technology receives US patent

February 21, 2018 | Wednesday | News

Egalet Announces Issuance of New U.S. Patent for Guardian™ Technology

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, has received a US patent for its proprietary Guardian Technology.

The patent covers the Guardian Technology two-component tablet architecture which provides precise drug delivery and can confer abuse-deterrent properties.

The United States Patent and Trademark Office (USPTO) have issued patent number 9,884,029 covering Egalet-002. The patent offers protection through March 2024.

Egalet has been granted a total of 20 US patents and 59 patents outside of the US that cover Guardian Technology and its product candidate

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy